Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Intesity Therapeutics Inc INTS

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.


NDAQ:INTS - Post by User

User Avatar Image
(1491)
•••
  • IseneschalX
Post by Iseneschalon Oct 30, 2025 2:14pm
23 Views
Post# 36768676

INTS....Halted ...but hang on a minute!!!!

INTS....Halted ...but hang on a minute!!!!This a RS candidate....it was voted on last meeting....here ....read this and u be the judge:

https://www.sec.gov/Archives/edgar/data/1567264/000156726425000096/intensity-20251022.htm
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities